News
Please, enter cell line, author or any other phrase or word you would like to search for.
PHI announces conference schedule for spring 2024
PHI is pleased to announce a strategic activity schedule for spring 2024, during which PHI will participate in select industry webinars and events.
Interim Report 3 2023/24
This quarter set new records for PHI, achieving our highest-ever sales and advancing our strategic initiatives significantly. The strengthening of our partnership with Altium and the expanding reach of QPI technology highlights our leading position in the field. This quarter truly shows our continuous progress toward our core mission: making cell-based therapies accessible, affordable, and safe for all.
BioStock: Shift to regenerative medicine increases growth prospects for PHI
BioStock talked to our CEO, Patrik Eschricht, for an operational overview and to learn about the current behind-the-scenes developments, as PHI has a growth trajectory that is on a notable upward trend, marked by its highest-ever sales performances in the last quarter.
Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ) 14 March 2024
On Thursday, March 14, 2024, Phase Holographic Imaging PHI AB (publ), held an extraordinary general meeting. The following resolutions were passed at the meeting.
Shaping the future of Regenerative Medicine – PHI’s vision for QPI in Cell Therapy Manufacturing
PHI presents a comprehensive opinion piece detailing the versatility and potential the Company sees for Quantitative Phase Imaging (QPI) technology in Regenerative Medicine. PHI outlines how QPI will offer enhanced cell quality control in the cell manufacturing process, thereby addressing a central puzzle piece for making cell-based therapies safe, affordable, and accessible for all.
New Distributor Partner Manager at Altium set to enhance global sales for PHI
PHI is conveying the news that its global distributor, Altium ., has appointed a PHI-dedicated distributor partner manager. This strategic step is set to significantly enhance the reach and sales performance of PHI’s HoloMonitor technology on a global scale.
Notice of extraordinary general meeting in Phase Holographic Imaging PHI AB 14 March 2024
Phase Holographic Imaging PHI AB (publ), 556542-7811 (the “Company”) will hold an extraordinary general meeting on 14 March 2024 at 10.00 am at the Company’s premises, Skiffervägen 48 in Lund.
BioStock: PHI “We aim to revolutionize the regenerative medicine market“
BioStock talked to PHI’s CEO, Patrik Eschricht, about the eventful past year and his vision for the company’s future within regenerative medicine.
PHI presents at the Redeye Regenerative Medicine & Cell Therapy 2024
PHI is delighted to participate in the Redeye Regenerative Medicine and Cell Therapy event on Wednesday, February 14, 2024.
PHI announces extraordinary quarter sales of about 5MSEK — marks the highest ever in Company history
PHI is excited to announce that preliminary Q3 net sales are summing up to approximately 5MSEK. These extraordinary quarterly net sales make it the highest ever in the Company’s history and mark an important financial milestone.